Published in final edited form as:

Orthod Craniofac Res. 2010 November ; 13(4): 214–222. doi:10.1111/j.1601-6343.2010.01497.x.

Ovariectomy Stimulates and Bisphosphonates Inhibit Intracortical Remodeling in the Mouse Mandible

Daniel J. Kubek¹, David B. Burr^{1,2,3}, and Matthew R. Allen¹

¹ Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN

² Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN

³ Department of Biomedical Engineering Program Indiana University-Purdue University Indianapolis, Indianapolis, IN

Abstract

Objective—The pathophysiology of osteonecrosis of the jaw (ONJ) is thought to be linked to suppression of intracortical remodeling. Aim of this study was to determine whether mice, which normally do not undergo appreciable amounts of intracortical remodeling, could be stimulated by ovariectomy to remodel within the cortex of the mandible and if bisphosphonates (BPs) would suppress this intracortical remodeling.

Material and Methods—Skeletally mature female C3H mice were either ovariectomized (OVX) or SHAM operated and treated with two intravenous doses of zoledronic acid (ZOL, 0.06 mg/kg body weight) or vehicle (VEH). This ZOL dose corresponds to the dose given to cancer patients on a mg/kg basis, adjusted for body weight. Calcein was administered prior to sacrifice to label active formation sites. Dynamic histomorphometry of the mandible and femur were performed.

Results—Vehicle-treated OVX animals had significantly higher (8-fold) intracortical remodeling of the alveolar portion of the mandible compared to sham – this was significantly suppressed by ZOL treatment. At all skeletal sites, overall bone formation rate (BFR) was lower with ZOL treatment compared to the corresponding VEH group.

Conclusions—Under normal conditions the level of intracortical remodeling in the mouse mandible is minimal but in C3H mice can be stimulated to appreciable levels with ovariectomy. Based on this, if the suppression of intracortical remodeling is found to be part of the pathophysiology of ONJ, the ovariectomized C3H mouse could serve as a useful tool for studying this condition.

Keywords

BRONJ; jaw necrosis; osteonecrosis; ONJ; zoledronic acid

CLINICAL RELEVANCE

Osteonecrosis of the jaw is a rare but serious side effect of bisphosphonate treatment. The pathophysiology of this condition remains unclear due in part to the absence of an animal model. A key factor in the etiology of the condition is thought to be suppression of

intracortical remodeling. We show here for the first time that the mandible of mice can be stimulated to undergo intracortical remodeling by ovariectomy and this increased remodeling is suppressed with bisphosphonates. These results suggest this mouse strain may be useful in the development of an animal model for osteonecrosis of the jaw.

Introduction

Bisphosphonates (BPs) are a drug class that is widely and effectively used in the treatment of osteoporosis, Paget's disease and metastatic cancers involving bone. BPs are associated with a rare condition known as osteonecrosis of the jaw (ONJ) (1,2). Zoledronic acid (Zometa), the BP most often used in treating cancer patients, is most often associated with ONJ. This condition is characterized by regions of exposed, necrotic bone in the mandible and/or maxilla (3,4). Unfortunately, little is known about the pathogenesis of ONJ due in part to the absence of an animal model for this condition (3,5).

The mandible undergoes intracortical remodeling at a faster rate than other cortical bone regions in the body (6,7). Many have suggested that ONJ is related to remodeling suppression (1,5). Consistent with this theory, BPs have been shown to impart near complete suppression of intracortical remodeling in the mandible of beagle dogs (7) and this is associated with an accumulation of necrotic bone matrix (6).

Unlike humans and other larger animals, rodents do not routinely undergo appreciable amounts of intracortical remodeling (8). This potentially limits the use of rats and mice as an animal model for ONJ, if suppression of intracortical remodeling is a part of the disease etiology. Recent data have documented that adult C3H mice undergo significant amounts of intracortical remodeling in the femur mid-diaphysis following ovariectomy (9). Whether or not similar increases in intracortical remodeling occur in the mandible following OVX is not clear. If they do, it's possible this mouse strain could be valuable as a model to study ONJ.

Therefore, the goal of this study was to determine whether or not the C3H mouse undergoes significant intra-cortical bone remodeling in the mandible following ovariectomy. We hypothesized that the mandible of C3H mice would undergo higher levels of intracortical remodeling with ovariectomy and that intravenous zoledronic acid would suppress this increased remodeling.

Materials and Methods

Skeletally-mature female C3H mice (n=33) were obtained from Harlan at 16 weeks of age and divided into two groups; ovariectomized (OVX, n=17) and SHAM operated (n=16). Within each group, some of the animals were treated with zoledronic acid (ZOL) and the remaining animals were treated with physiologic saline vehicle (VEH). Ovariectomy surgeries were performed at Harlan, where the mice were housed for 7 days post-OVX prior to shipment to IU School of Medicine (IUSM) where they were housed 7 days prior to any intervention. Animals were housed four per cage (within treatment group) in the LARC facility and monitored daily for general health and any abnormal effects of treatment. All animal procedures were approved prior to the study by the IUSM Animal Care and Use Committee.

Animals in the ZOL treatment group received the drug via intravenous infusion at weeks 3 and 6 post-OVX. ZOL concentrations were based on the 4mg drug dose given to cancer patients assuming a 60kg individual, adjusted on a mg/kg basis (0.06 mg/kg body weight dissolved in 0.2 mL sterile saline). VEH animals received 0.2 mL IV physiologic saline

vehicle at the same time points as ZOL treatment. All IV infusions were administered through the tail vein using a 27 gauge needle over a 3-5 minute period while the animal was contained within an animal restrainer. Calcein (0.2 ml/kg @ 30mg/kg) was administered intraperitoneally at 14 and 4 days prior to sacrifice to label active formation sites. The animals were euthanized at 24 weeks of age (CO₂ inhalation with death confirmed by inducing bilateral pneumothorax). The mandibles and femurs were collected at necropsy and fixed in 10% neutral buffered formalin. The absence/presence of ovaries was confirmed at necropsy.

Histology

Mandible and femoral tissues were processed undecalcified for histological analyses using standard methods (10). To determine if any bone matrix necrosis existed in these tissues, all specimens were stained with 1% basic fuchsin dissolved in increasing ethanol concentrations (70%, 95%, and 100%) each for 4 hours (6). Mandibles were sectioned (~100um thick) throughout the molar region by making successive buccal-lingual cuts in the frontal plane using a diamond wire saw (Histosaw; Delaware Diamond Knives) (Figure 1). Femurs were sectioned (~100um thick) at the mid-diaphysis.

Histological measurements were made using a semiautomatic analysis system (Bioquant OSTEO 7.20.10, Bioquant Image Analysis Co.) attached to a microscope (Nikon Optiphot 2 microscope, Nikon) with a fluorescent light source. For the mandible, dental landmarks were used to choose one section for analysis at a similar rostral/caudal region among all animals. Specifically, we chose the section that contained the deepest root of the first molar tooth as this provided us the opportunity to assess the greatest amount of alveolar bone in our analysis. This method of section selection was chosen in order to provide consistency in the anatomy of the section across all animals. For the mandible sections, data were collected separately for alveolar cortical bone (defined as cortical bone above the most distally observed portion of the tooth root) and the non-alveolar cortical bone (the cortical tissue inferior to the apex of the tooth root) (Figure 1). In the alveolar mandible, the total surface of bone immediately adjacent to the tooth root where attachment of the periodontal ligament occurs was measured for the amount of calcein labeling (Figure 1). In addition to the cortical bone of the non-alveolar mandible, the trabecular bone surfaces (found just below the apex of the molar) were also measured for amount of calcein labeling within the region of interest. The cortical bone of the entire cross section of femur was assessed for intracortical bone label.

For measures of intracortical remodeling, total bone area (B.Ar), number of labeled osteons (L.On.#, osteons with either single or double label), the total length of osteon labeled surface (LS), and the mean inter-label distance (Ir.L.Wi) were determined. Osteons were defined as structures within the cortical bone that contained single or double label (Figure 2A, 2B), – resorption spaces without label were not counted in this analysis. For surface-based assessments total bone surface (BS), surfaces with either single or double label (sLS and dLS, respectively) and Ir.L.Wi were measured. As calcein labels were injected on two different occasions, measurements are separately for surfaces having single label surface (indicative of active bone formation at one of the two times of calcein injection) and double label surface (indicative of active bone formation at both times of calcein administration). Mineral apposition rate (MAR, um/day) was calculated as $\text{Ir.L.Wi} / 10$, where 10 is the number of days between labels. Intra-cortical bone formation rate (BFR, %/year) was calculated as $(\text{MAR} \times (\text{LS}/2) / \text{B.Ar} \times 100) \times 365$. Surface-based mineralizing surface (MS/BS, %) was calculated as $((0.5 \times \text{sLS}) + \text{dLS}) / \text{BS} \times 100$. Surface-based bone formation rate (BFR, $\text{um}^3/\text{um}^2/\text{year}$) was calculated as $\text{MAR} \times (\text{MS}/\text{BS}/100) \times 365$. For animals with only singly labeled osteons, a value of 0.3 was used for MAR (11); if no label was present, MAR was considered to be a missing value and BFR was considered to be 0 to reflect the absence

of any bone formation activity. All measures and calculations are in accordance with ASBMR recommended standards (12).

Statistics

All statistical analyses were performed using SAS statistical software (SAS Institute, Inc.). Two-way ANOVA tests were used to determine the main effects of surgery (SHAM versus OVX) and treatment (VEH versus ZOL) as well as their interaction. Significant interactions were further assessed by one-way ANOVA to determine specific group differences. Post-hoc comparisons were made using Fisher's PLSD tests. For all tests, $p < 0.05$ was used to determine statistical significance.

Results

Bone Matrix Necrosis

No areas of bone matrix necrosis were noted in either the mandible or femur of any animal. This assessment consisted of examining five cross-sections of the mid-diaphysis femur and between 8 and 15 sections of mandible for each animal.

Mandible: Alveolar and Non-alveolar Cortical Bone

In the alveolar bone of the mandible, there was no significant difference in intracortical MAR or labeled osteon number among the four treatment groups (Table 1). There was a significant interaction between surgery and treatment for alveolar bone BFR (Table 1 and Figure 3A). In VEH-treated animals, BFR was significantly higher in OVX (>7-fold) compared to SHAM while in ZOL-treated animals BFR was 75% lower in OVX compared to SHAM. There was no significant difference between VEH-SHAM and ZOL-SHAM. In the non-alveolar cortical bone of the mandible there was no significant difference in any of the parameters measured among groups (Table 1).

Mandible: Periodontal Ligament & Trabecular Bone Surfaces

On the periodontal ligament attachment surface of the alveolar cortical bone there was no significant effect of surgery, drug treatment or an interaction between the two interventions for MAR, MS/BS or BFR (Table 2). On the trabecular bone surfaces of the mandible, there were significant effects of both surgery and ZOL treatment (Table 2). Trabecular MS/BS showed both a significant surgery and treatment effect with no significant interaction between the main effects. ZOL-treated animals had a 59% lower MS/BS and a 58% lower BFR compared to VEH-treated animals (Table 2 and Figure 3B).

Tooth Dentin Mineralization Rate

During our measures of calcein labeling in the mandible, we observed clear and consistent double calcein labeling within the incisor tooth dentin (Figure 2A). We therefore measured mineral apposition rate to determine if there was any effect of either surgery or treatment in dentin mineralization rate. There was no significant difference due to surgery or ZOL-treatment on dentin MAR (Table 2).

Femur

Femoral intracortical bone parameters were all significantly affected by ZOL-treatment, but not surgery. There was also no interaction between the two interventions. MAR and labeled osteon number were both significantly lower in ZOL-treated animals compared to VEH (-27% and -37%, respectively). These changes combined to produce a significantly lower intracortical BFR (-65%) in ZOL compared to VEH treated animals (Table 3 and Figure 3C).

Discussion

For several years now, bisphosphonates have been linked to ONJ (1,2). Although recent studies have emerged showing potential models of ONJ in mice (13), rats (14-20), and dogs (21,22), there remains no clear animal model that parallels ONJ etiology and pathophysiology. The most prominently proposed mechanism for ONJ involves remodeling suppression. This hypothesis, as opposed to a specific effect of bisphosphonates on the bone/soft tissue, is further supported by the recent case reports of ONJ in patients treated with denosumab (23). Denosumab, a human monoclonal antibody that inhibits osteoclast development by targeting RANK ligand acts through a different mechanism than bisphosphonates and does not accumulate in the skeleton. One prominent similarity between bisphosphonates and denosumab is that they both significantly suppress bone remodeling.

It is generally accepted that rodents do not naturally undergo significant amounts of intracortical remodeling in their long bones or the mandible (8) and therefore their utility as a model for ONJ has been questioned (24,25). Previously, Li et al (9) have shown that ovariectomy in C3H mice elicits a significant increase in intracortical remodeling of the femur. Our study expands this work by showing that intracortical remodeling occurs also within the mandible, specifically within the alveolar portion, of C3H mice following ovariectomy. In VEH treated animals, we showed over a 7-fold higher alveolar BFR due to OVX compared to SHAM operated animals. Consistent with the low, but measurable intracortical alveolar BFR in our SHAM group, osteons were noted in the mandible/maxilla of 17 week old C3H mice although these existed in only some animals and were low in number (26). Our study also documents that ZOL-treatment prevented the OVX-induced elevation in intracortical remodeling of the alveolar cortical bone. This is consistent with the suppression of intracortical remodeling at various sites in humans (27,28) and in the alveolar bone of dogs (6,7).

Histomorphometry is the gold-standard method for assessment of bone remodeling. Although other methods, such as serum or urine biomarkers can provide whole body estimates of remodeling, only histology can provide site-specific remodeling data. In the current work, we used the standard technique of fluorochrome labeling to denote actively forming bone surfaces. By injecting calcein, which binds to calcium being incorporated into hydroxyapatite during mineralization, it is possible to determine parameters such as mineral apposition rate (the rate at which bone is formed at an individual site), mineralizing surface (the number of actively forming surface), and bone formation rate (the rate bone is forming at a tissue-level). As mature animals predominantly undergo remodeling (the coupled process of resorption and formation) on trabecular surfaces and exclusively undergo remodeling within the cortex, assessment of bone formation rate in these bone envelopes gives insight into the rate of remodeling. As formation-based modeling occurs on periodontal ligament surfaces, BFR on this surface is directly related to osteoblast-mediated bone formation.

The effect of ZOL was also evident in the current study by the lower remodeling of the mandible trabecular bone, with ZOL-treated animals having a 42% lower BFR compared to VEH. We did not find a significant difference in OVX versus SHAM animals for trabecular BFR. Previous work has shown that the OVX-induced increase in remodeling in rodents occurs acutely but is then lost over time (29). Thus it's possible that our assessment eight weeks post-ovariectomy missed the period when BFR was stimulated. Alternatively it's possible that the response to ovariectomy differs in this trabecular bone in the mandible compared to more traditionally assessed sites (vertebra or proximal tibia).

The surface adjacent to the periodontal ligament primarily undergoes bone modeling (30). We found no significant effect of either surgery or drug-treatment on this surface. Recent reports from our lab have shown that bisphosphonates, including ZOL, do not affect formation bone modeling in ovariectomized animals (31). Previous work in B6 mice showed ZOL significantly suppressed mandible periosteal surface bone formation rate, a surface that also primarily undergoes modeling activity (32). The discrepancy between these previous data and the current study are not clear although it's likely due to either the differences in mouse strain (B6 versus C3H) or the ZOL dosing schedule. The current study administered two doses ZOL while the previous study administered weekly ZOL (9 total doses); it's possible that these higher doses could produce a suppressive effect on osteoblast activity.

In accordance with Li et al. (9), our study showed a 27% higher intracortical BFR in the femur of OVX-VEH compared to SHAM-VEH although this was not statistically significant. The discrepancy between the previous and current work could be the result of the technique used to assess intracortical remodeling where Li et al counted both labeled osteons and resorption spaces while we excluded the latter. We opted to only assess labeled osteons to provide the most conservative assessment of intracortical activity as there existed regions in the mandible in which distinguishing between an unlabeled resorption space and a trabecular surface proved difficult. Intracortical remodeling of the femur was significantly reduced with ZOL treatment, consistent with studies in larger animals treated with either ZOL or other bisphosphonates (7,33).

In both the femora and mandibles, prior to sectioning, all specimens were stained en bloc with basic fuchsin to elucidate regions of bone matrix necrosis, defined as regions of bone devoid of stain, demarcating regions of non-viable bone (34,35). No regions of bone matrix necrosis were noted in this study, likely due to the short treatment duration. We have previously shown significant accumulation of necrotic matrix existed within the mandible of beagle dogs treated for 1 or 3 years of daily oral alendronate (6,22) yet not in animals treated for 3 or 6 months (7). This suggests a time-dependent factor in the development of matrix necrosis which makes some sense as the region would need to have time for the local canalicular network to fill with mineral. We hypothesize that longer duration of bisphosphonate treatment following ovariectomy in this mouse strain would result in accumulation of necrotic bone matrix.

Nearly 20 years ago, prolonged treatment with clodronate in young growing rats was shown to produce necrotic bone fragments projecting through the oral mucosa (20). More recently, several publications have suggested ONJ can be produced in rodents. These studies have involved mainly treatment of rats with high doses of ZOL with or without concomitant treatment with dexamethasone or dental surgery (14-16,18). One study in B6 mice, has also shown ZOL and/or dexamethasone combined with tooth extraction revealed ONJ-like lesions (13). Although these rodent models necessitate further validations, the emerging evidence suggests the rodent may serve as an important animal model for studying ONJ. Unfortunately none of these studies assessed intracortical bone remodeling. Significant suppression of intracortical remodeling and formation of exposed bone and sequestra has been recently documented in beagle dogs treated with zoledronic acid and subjected to dental extraction (21).

Conclusion

In conclusion, we show that ovariectomy of skeletally mature C3H inbred mice stimulates intracortical remodeling in the mandible, especially in the alveolar region. Furthermore, we show that bisphosphonate treatment significantly suppresses this intracortical remodeling. If suppression of intracortical remodeling proves to be important in the etiology of

osteonecrosis of the jaw then the ovariectomized C3H mouse may prove useful as an animal model to study this condition.

Acknowledgments

The authors would like to thank Keith Condon for assistance with histological processing, Anthony Feher for assistance with animal tissue collection, and Carrie Pell for assistance with animal dosing. This work was supported by a grant from the NIH (R21-DE019686).

References

1. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. *Journal of Oral and Maxillofacial Surgery* 2005;63:1567–75. [PubMed: 16243172]
2. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. *Journal of Oral and Maxillofacial Surgery* 2004;62:527–34. [PubMed: 15122554]
3. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. *Journal of Bone and Mineral Research* 2007;22:1479–91. [PubMed: 17663640]
4. Ruggiero SL, Mehrotra B. Bisphosphonate-Related Osteonecrosis of the Jaw: Diagnosis, Prevention, and Management. *Annual Review of Medicine* 2009;60:85–96.
5. Allen MR, Burr DB. The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data. *Journal of Oral and Maxillofacial Surgery* 2009;67:61–70. [PubMed: 19371816]
6. Allen MR, Burr DB. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. *Journal of Oral and Maxillofacial Surgery* 2008;66:987–94. [PubMed: 18423290]
7. Allen MR, Kubek DJ, Burr DB. Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. *Journal of Bone and Mineral Research* 2010;25:98–105. [PubMed: 19580463]
8. Jowsey J. Studies of Haversian systems in man and some animals. *J Anat* 1966;100:857–64. [PubMed: 4961449]
9. Li CY, Schaffler MB, Wolde-Semait HT, Hernandez CJ, Jepsen KJ. Genetic background influences cortical bone response to ovariectomy. *J Bone Miner Res* 2005;20:2150–8. [PubMed: 16294268]
10. Allen MR, Iwata K, Phipps R, Burr DB. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. *Bone* 2006;39:872–79. [PubMed: 16765660]
11. Foldes J, Shih MS, Parfitt AM. Frequency distributions of tetracycline-based measurements: implications for the interpretation of bone formation indices in the absence of double-labeled surfaces. *J Bone Miner Res* 1990;5:1063–7. [PubMed: 2080717]
12. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, et al. Bone Histomorphometry - Standardization Of Nomenclature, Symbols, And Units. *Journal of Bone and Mineral Research* 1987;2:595–610. [PubMed: 3455637]
13. Kikuri T, Kim I, Yamaza T, Akiyama K, Zhang Q, Li Y, et al. Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. *Journal of Bone and Mineral Research* 2010;9999 n/a.
14. Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. *Oral Oncology* 2009;45:164–72. [PubMed: 18715819]
15. Biasotto M, Chiandussi S, Zacchigna S, Moimas S, Dore F, Pozzato G, et al. A novel animal model to study non-spontaneous bisphosphonates osteonecrosis of jaw. *J Oral Pathol Med*. 2010

16. Hokugo A, Christensen R, Chung E, Sung E, Felsenfeld AL, Sayre JW, et al. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. *J Bone Miner Res*. 2010
17. Hikita H, Miyazawa K, Tabuchi M, Kimura M, Goto S. Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats. *J Bone Miner Metab* 2009;27:663–72. [PubMed: 19436946]
18. Senel FC, Duman MK, Muci E, Cankaya M, Pampu AA, Ersoz S, et al. Jaw bone changes in rats after treatment with zoledronate and pamidronate. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology* 2010;109:385–91.
19. Kobayashi Y, Hiraga T, Ueda A, Wang L, Matsumoto-Nakano M, Hata K, et al. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. *Journal of Bone and Mineral Metabolism* 2010;28:165–75. [PubMed: 19882100]
20. Gotcher JE, Jee WS. The progress of the periodontal syndrome in the rice rat. II. The effects of a diphosphonate on the periodontium. *J Periodontal Res* 1981;16:441–55. [PubMed: 6459441]
21. Allen MR, Chu TG, Kubek D, Burr DB. Compromised Osseous Healing of Dental Extraction Sites in Zoledronic Acid-Treated Dogs. *Osteoporos Int*. In press.
22. Burr DB, Allen MR. Mandibular necrosis in beagle dogs treated with bisphosphonates. *Orthodontics & Craniofacial Research* 2009;12:221–28. [PubMed: 19627524]
23. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the Jaw in a Patient on Denosumab. *J Oral Maxillofac Surg*. 2010
24. Allen MR. Animal models of osteonecrosis of the jaw. *J Musculoskelet Neuronal Interact* 2007;7:358–60. [PubMed: 18094512]
25. Allen, MR. Bisphosphonates and Osteonecrosis of the Jaw: Moving from the Bedside to the Bench. *Karger*; 2009. p. 289-94.
26. Meta IF, Fernandez SA, Gulati P, Huja SS. Alveolar Process Anabolic Activity in C3H/HeJ and C57BL/6J Inbred Mice. *Journal of Periodontology* 2008;79:1255–62. [PubMed: 18597609]
27. Borah B, Dufresne T, Nurre J, Phipps R, Chmielewski P, Wagner L, et al. Risedronate reduces intracortical porosity in women with osteoporosis. *Journal of Bone and Mineral Research* 2010;25:41–47. [PubMed: 19580469]
28. Smith SY, Recker RR, Hannan M, Muller R, Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. *Bone* 2003;32:45–55. [PubMed: 12584035]
29. Baumann BD, Wronski TJ. Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. *Bone* 1995;16:247–53. [PubMed: 7756054]
30. Melsen B. Tissue reaction to orthodontic tooth movement--a new paradigm. *Eur J Orthod* 2001;23:671–81. [PubMed: 11890063]
31. Feher A, Koivunemi A, Koivunemi M, Fuchs RK, Burr DB, Phipps RJ, et al. Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading. *Bone* 2010;46:203–07. [PubMed: 19857619]
32. Huja SS, Fernandez SA, Phillips C, Li Y. Zoledronic acid decreases bone formation without causing osteocyte death in mice. *Archives of Oral Biology* 2009;54:851–56. [PubMed: 19591974]
33. Allen MR, Reinwald S, Burr DB. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. *Calcified Tissue International* 2008;82:354–60. [PubMed: 18463913]
34. Enlow DH. Osteocyte necrosis in normal bone. *J Dent Res* 1966;45:213. [PubMed: 4955384]
35. Frost HM. Micropetrosis. *J Bone Joint Surg Am* 1960;42-A:144–50. [PubMed: 13849862]

Figure 1.

Region of assessment in mouse mandible. Upper panel is a photograph of the mouse hemimandible showing molar region where histological sections were obtained. Lower panel shows a CT image (for illustration purposes only, no CT was done in this study) of the region similar to that assessed histologically. The line at the base of the tooth root separates the alveolar from the non-alveolar bone, the two regions of intracortical bone analyses. Arrows show the periodontal ligament bone surface on which assessment of calcein labeled surface was made. The box represents the region for trabecular bone analyses.

Figure 2a

Figure 2b

Figure 2. Photomicrograph of basic fuchsin-stained mandible (A) and femur (B) viewed with fluorescent light. Insets show actively remodeling intracortical osteons. Dotted arrows in (A) show the periodontal ligament bone surface on which assessment of calcein labeled surface was made; solid arrows show the location of dentin mineral apposition rate measures.

Figure 3.

Ovariectomy stimulates and zoledronic acid (ZOL) reduces remodeling activity in C3H mouse. (A) In alveolar cortical bone of the mandible, vehicle (VEH) treated ovariectomized (OVX) animals had >7-fold higher bone formation rate (BFR) compared to SHAM and this was significantly suppressed by ZOL. (B) Trabecular bone of the mandible showed ZOL-treated animals had a 58% lower BFR compared to VEH. (C) Femur intracortical remodeling was significantly suppressed in ZOL-treated animals compared to VEH treated animals. Data presented as mean + SE. $p < 0.05$ vs. Sham within treatment (a), within surgery between drug (b).

Table 1
Effects of ovariectomy surgery and zoledronic acid on intracortical remodeling of the mandible.

	Vehicle		Zoledronic Acid		P-values		
	Sham	OVX	Sham	OVX	Surgery	Drug	Int.
ALVEOLAR CORTICAL BONE							
Mineral Apposition Rate ($\mu\text{m}/\text{day}$)	0.35 ± 0.05	0.62 ± 0.15	0.33 ± 0.03	0.30 ± 0.00	NS	NS	NS
Labeled Osteon Number ($\#/\text{mm}^2$)	2.19 ± 0.80	3.81 ± 0.90	2.69 ± 0.93	1.52 ± 0.51	NS	NS	NS
NON-ALVEOLAR CORTICAL BONE							
Mineral Apposition Rate ($\mu\text{m}/\text{day}$)	0.52 ± 0.22	0.30 ± 0.00	-	0.30 ± 0.00	NS	NS	NS
Labeled Osteon Number ($\#/\text{mm}^2$)	0.72 ± 0.39	0.33 ± 0.33	0	0.69 ± 0.29	NS	NS	NS
Bone Formation Rate ($\mu\text{m}^3/\mu\text{m}^2/\text{year}$)	0.48 ± 0.27	0.11 ± 0.11	0	0.20 ± 0.10	NS	NS	NS

NS, non-significant.

Effects of ovariectomy surgery and zoledronic acid on mandible trabecular bone, periodontal ligament cortical bone surface, and dentin formation activity

Table 2

	Vehicle		Zoledronic Acid		P-values		
	Sham	OVX	Sham	OVX	Surgery	Drug	Int.
MANDIBLE TRABECULAR BONE							
Mineral Apposition Rate ($\mu\text{m}/\text{day}$)	0.73 $\pm$ 0.03	0.74 $\pm$ 0.03	0.68 $\pm$ 0.07	0.75 $\pm$ 0.03	NS	NS	NS
Mineralizing surface / Bone surface (%)	25.75 $\pm$ 1.94	19.89 $\pm$ 2.34	16.14 $\pm$ 4.13	10.89 $\pm$ 1.78	p < .05	p < .05	NS
PERIODONTAL LIGAMENT SURFACE							
Mineral Apposition Rate ($\mu\text{m}/\text{day}$)	0.48 $\pm$ 0.04	0.60 $\pm$ 0.03	0.64 $\pm$ 0.11	0.60 $\pm$ 0.05	NS	NS	NS
Mineralizing surface / Bone surface (%)	14.20 $\pm$ 1.30	14.61 $\pm$ 2.46	11.39 $\pm$ 1.49	11.88 $\pm$ 1.75	NS	NS	NS
Bone Formation Rate ($\mu\text{m}^3/\mu\text{m}^2/\text{year}$)	24.52 $\pm$ 3.31	33.12 $\pm$ 7.11	26.39 $\pm$ 4.41	27.36 $\pm$ 5.29	NS	NS	NS
DENTIN							
Mineral Apposition Rate ($\mu\text{m}/\text{day}$)	4.17 $\pm$ 0.05	4.33 $\pm$ 0.07	4.07 $\pm$ 1.34	4.13 $\pm$ 0.08	NS	NS	NS

NS, non-significant.

Table 3
Effect of ovariectomy surgery and zoledronic acid treatment on intracortical remodeling of the femur.

	<u>Vehicle</u>		<u>Zoledronic Acid</u>		<u>P-values</u>		
	Sham	OVX	Sham	OVX	Surgery	Drug	Int.
Mineral Apposition Rate ($\mu\text{m}/\text{day}$)	1.58 $\pm$ 0.11	2.13 $\pm$ 0.19	1.22 $\pm$ 0.20	1.48 $\pm$ 0.23	NS	p < .05	NS
Labeled Osteon Number ($\#/\text{mm}^2$)	4.45 $\pm$ 0.82	4.23 $\pm$ 0.95	2.46 $\pm$ 0.57	2.93 $\pm$ 0.49	NS	p < .05	NS

NS, non-significant.